Astrocytic damage is far more severe than demyelination in NMO
A clinical CSF biomarker study
Abstract
Introduction: Loss of aquaporin 4 and glial fibrillary acidic protein (GFAP) with necrosis and demyelination is a prominent pathologic feature of neuromyelitis optica (NMO). However, the clinicopathologic significance of astrocytic damage and its relation with demyelination are unknown.
Objective: To analyze clinical and pathologic values of a CSF biomarker of astrocytic damage in NMO.
Methods: We measured the levels of GFAP, S100B, myelin basic protein (MBP), and neurofilament H (NF-H) in CSF obtained from patients with NMO (n = 33), multiple sclerosis (MS) (n = 27), acute disseminated encephalomyelitis (ADEM), ischemia, meningitis, and other neurologic disease controls (OND).
Results: The CSF-GFAP levels during relapse in NMO (2,476.6 ± 8,815.0 ng/mL) were significantly higher than those in MS (0.8 ± 0.4 ng/mL) and OND (0.7 ± 0.5 ng/mL), and much beyond those in ADEM (14.1 ± 27.4 ng/mL). The sensitivity and specificity of CSF-GFAP for NMO was 90.9% and 76.9% in all, but the specificity improved above 90% in cases limited to demyelinating diseases. CSF-S100B showed a similar trend but was less remarkable. In contrast, MBP and NF-H are not different between NMO and MS. Following treatments, the CSF-GFAP rapidly decreased to a normal level, but CSF-MBP remained high. There were strong correlations between the CSF-GFAP, CSF-S100B, or CSF-MBP levels and Expanded Disability Status Scale (EDSS) or spinal lesion length in the acute phase (r > 0.6). Only CSF-GFAP correlated with EDSS at 6-month follow-up (r = 0.51) in NMO.
Conclusions: Astrocytic damage reflected by elevated CSF glial fibrillary acidic protein is a clinically relevant, primary pathologic process in neuromyelitis optica, and is far more severe than demyelination.
Get full access to this article
View all available purchase options and get full access to this article.
REFERENCES
1.
Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG. The spectrum of neuromyelitis optica. Lancet Neurol 2007;6:805–815.
2.
Misu T, Fujihara K, Nakashima I, et al. Pure optic-spinal form of multiple sclerosis in Japan. Brain 2002;125:2460–2468.
3.
Kira J. Multiple sclerosis in the Japanese population. Lancet Neurol 2003;2:117–127.
4.
Wingerchuk DM, Hogancamp WF, O'Brien PC, Weinshenker BG. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology 1999;53:1107–1114.
5.
Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004;364:2106–2112.
6.
Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 2005;202:473–477.
7.
Misu T, Fujihara K, Nakamura M, et al. Loss of aquaporin-4 in active perivascular lesions in neuromyelitis optica: a case report. Tohoku J Exp Med 2006;209:269–275.
8.
Misu T, Fujihara K, Kakita A, et al. Loss of aquaporin 4 in lesions of neuromyelitis optica: distinction from multiple sclerosis. Brain 2007;130:1224–1234.
9.
Roemer SF, Parisi JE, Lennon VA, et al. Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. Brain 2007;130:1194–1205.
10.
Hinson SR, Pittock SJ, Lucchinetti CF, et al. Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis optica. Neurology 2007;69:2221–2231.
11.
Giovannoni G. Multiple sclerosis cerebrospinal fluid biomarkers. Dis Markers 2006;22:187–196.
12.
Misu T, Takano R, Fujihara K, Takahashi T, Sato S, Itoyama Y. Marked increase in cerebrospinal fluid glial fibrillar acidic protein in neuromyelitis optica: an astrocytic damage marker. J Neurol Neurosurg Psychiatry 2009;80:575–577.
13.
Whitaker JN. Myelin encephalitogenic protein fragments in cerebrospinal fluid of persons with multiple sclerosis. Neurology 1977;27:911–920.
14.
Cohen SR, Brooks BR, Herndon RM, McKhann GM. A diagnostic index of active demyelination: myelin basic protein in cerebrospinal fluid. Ann Neurol 1980;8:25–31.
15.
Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006;66:1485–1489.
16.
Takahashi T, Fujihara K, Nakashima I, et al. Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre. Brain 2007;130:1235–1243.
17.
McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001;50:121–127.
18.
Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444–1452.
19.
Sejvar JJ, Kohl KS, Bilynsky R, et al. Encephalitis, myelitis, and acute disseminated encephalomyelitis (ADEM): case definitions and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine 2007;25:5771–5792.
20.
Akman-Demir G, Serdaroglu P, Tasci B. Clinical patterns of neurological involvement in Behçet's disease: evaluation of 200 patients: The Neuro-Behcet Study Group. Brain 1999;122:2171–2182.
21.
Petzold A, Keir G, Green AJ, Giovannoni G, Thompson EJ. An ELISA for glial fibrillary acidic protein. J Immunol Methods 2004;287:169–177.
22.
Hinson SR, Roemer SF, Lucchinetti CF, et al. Aquaporin-4-binding autoantibodies in patients with neuromyelitis optica impair glutamate transport by down-regulating EAAT2. J Exp Med 2008;205:2473–2481.
23.
Vincent T, Saikali P, Cayrol R, et al. Functional consequences of neuromyelitis optica-IgG astrocyte interactions on blood-brain barrier permeability and granulocyte recruitment. J Immunol 2008;181:5730–5737.
24.
Kinoshita M, Nakatsuji Y, Moriya M, et al. Astrocytic necrosis is induced by anti-aquaporin-4 antibody-positive serum. Neuroreport 2009;20:508–512.
25.
Takano R, Misu T, Takahashi T, Izumiyama M, Fujihara K, Itoyama Y. A prominent elevation of glial fibrillary acidic protein in the cerebrospinal fluid during relapse in neuromyelitis optica. Tohoku J Exp Med 2008;215:55–59.
26.
Rosengren LE, Lycke J, Andersen O. Glial fibrillary acidic protein in CSF of multiple sclerosis patients: relation to neurological deficit. J Neurol Sci 1995;133:61–65.
27.
Petzold A, Eikelenboom MJ, Gveric D, et al. Markers for different glial cell responses in multiple sclerosis: clinical and pathological correlations. Brain 2002;125:1462–1473.
28.
Vissers JL, Mersch ME, Rosmalen CF, et al. Rapid immunoassay for the determination of glial fibrillary acidic protein (GFAP) in serum. Clin Chim Acta 2006;366:336–340.
29.
Nishiyama H, Knopfel T, Endo S, Itohara S. Glial protein S100B modulates long-term neuronal synaptic plasticity. Proc Natl Acad Sci USA 2002;99:4037–4042.
30.
Watanabe S, Nakashima I, Misu T, et al. Therapeutic efficacy of plasma exchange in NMO-IgG-positive patients with neuromyelitis optica. Mult Scler 2007;13:128–132.
31.
Hauser SL, Oksenberg JR. The neurobiology of multiple sclerosis: genes, inflammation, and neurodegeneration. Neuron 2006;52:61–76.
32.
Rosengren LE, Wikkelso C, Hagberg L. A sensitive ELISA for glial fibrillary acidic protein: application in CSF of adults. J Neurosci Methods 1994;51:197–204.
33.
Schipper HM, Liang JJ, Wang E. Quiescent and cycling cell compartments in the senescent and Alzheimer-diseased human brain. Neurology 1993;43:87–94.
34.
Poser CM, Brinar VV. The nature of multiple sclerosis. Clin Neurol Neurosurg 2004;106:159–171.
35.
Miyazawa I, Nakashima I, Petzold A, Fujihara K, Sato S, Itoyama Y. High CSF neurofilament heavy chain levels in neuromyelitis optica. Neurology 2007;68:865–867.
36.
Jarius S, Aboul-Enein F, Waters P, et al. Antibody to aquaporin-4 in the long-term course of neuromyelitis optica. Brain 2008;131:3072–3080.
37.
Greitz D. Cerebrospinal fluid circulation and associated intracranial dynamics: a radiologic investigation using MR imaging and radionuclide cisternography. Acta Radiol Suppl 1993;386:1–23.
Information & Authors
Information
Published In
Copyright
© 2010.
Publication History
Published online: July 19, 2010
Published in issue: July 20, 2010
Keyword
Authors
Metrics & Citations
Metrics
Citation information is sourced from Crossref Cited-by service.
Citations
Download Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.
Cited By
- High-performance bottom gate carbon nanotube field-effect transistor immunosensor for detecting glial fibrillary acidic protein: A biomarker for traumatic brain injury, International Journal of Biological Macromolecules, 311, (143884), (2025).https://doi.org/10.1016/j.ijbiomac.2025.143884
- Laboratory parameters as diagnostic indicators in venous hypertensive myelopathy, The Spine Journal, 25, 5, (956-965), (2025).https://doi.org/10.1016/j.spinee.2024.12.008
- The value of CSF diagnostic and prognostic biomarkers in NMOSD and MOGAD in real-life use, Multiple Sclerosis and Related Disorders, 94, (106302), (2025).https://doi.org/10.1016/j.msard.2025.106302
- Disease characteristics of NMOSD and their relationship with disease burden: Observations from a large single-center cohort, Journal of the Neurological Sciences, 467, (123311), (2024).https://doi.org/10.1016/j.jns.2024.123311
- Neurofilament heavy phosphorylated epitopes as biomarkers in ageing and neurodegenerative disease, Journal of Neurochemistry, 169, 2, (2024).https://doi.org/10.1111/jnc.16261
- Autoimmune astrocytopathy double negative for AQP4‐IgG and GFAP‐IgG: Retrospective research of clinical practice, biomarkers, and pathology, CNS Neuroscience & Therapeutics, 30, 9, (2024).https://doi.org/10.1111/cns.70042
- NMOSD and MOGAD: an evolving disease spectrum, Nature Reviews Neurology, 20, 10, (602-619), (2024).https://doi.org/10.1038/s41582-024-01014-1
- The Role of Glial Fibrillary Acidic Protein as a Biomarker in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder: A Systematic Review and Meta-Analysis, Medicina, 60, 7, (1050), (2024).https://doi.org/10.3390/medicina60071050
- Blood‐based inflammatory protein biomarker panel for the prediction of relapse and severity in patients with neuromyelitis optica spectrum disorder: A prospective cohort study, CNS Neuroscience & Therapeutics, 30, 6, (2024).https://doi.org/10.1111/cns.14811
- CSF sphingolipids are correlated with neuroinflammatory cytokines and differentiate neuromyelitis optica spectrum disorder from multiple sclerosis, Journal of Neurology, Neurosurgery & Psychiatry, 96, 1, (54-67), (2024).https://doi.org/10.1136/jnnp-2024-333774
- See more
Loading...
View Options
Login options
Check if you have access through your login credentials or your institution to get full access on this article.
Personal login Institutional LoginPurchase Options
The neurology.org payment platform is currently offline. Our technical team is working as quickly as possible to restore service.
If you need immediate support or to place an order, please call or email customer service:
- 1-800-638-3030 for U.S. customers - 8:30 - 7 pm ET (M-F)
- 1-301-223-2300 for customers outside the U.S. - 8:30 - 7 pm ET (M-F)
- [email protected]
We appreciate your patience during this time and apologize for any inconvenience.